Predictive value of IL28b gene polymorphism combined with pretreatment serum IP-10 quantification for response to peginterferon and ribavirin is enhanced in comparison with any of these biomarkers alone

摘要

The current invention relates to a method of combining genotype determination with pre-treatment serum level measurement of IP-10 to predict the outcome of a sustained virological response (SVR) or non-response to peginterferon and ribavirin for individual patients infected with HCV.